![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions surrounding GSK (GSK plc) over the past week showcased a blend of optimism and caution. On the positive side, many investors highlighted the company's improving financial health, with discussions noting a decrease in debt and a rise in profits alongside an expanding pipeline of new products. Notably, a participant mentioned the potential for share price doubling, remarking, "Per of 15-20 is a more sensible valuation." The sentiment was further buoyed by upgraded revenue forecasts, with growth expectations for core operating profits set at 6 to 8 percent.
However, concerns were also evident, particularly regarding a recent class-action lawsuit and significant stock sales by executives. Emma Walmsley's sale of over 120,000 shares was criticized, prompting discussions about its implications. One investor remarked, "This doesn't look good..." paralleling sentiments that the class-action could be detrimental despite positive company forecasts. Overall, while there remains significant investor interest and belief in GSK's potential, the shadow of litigation and executive transactions continues to inject a degree of skepticism into the discussions. Investor sentiment seems mixed, with many still willing to add to their positions while others express unease about the company's legal challenges and recent share price performance.
Show more
In the past week, GSK plc has announced significant transactions involving its Chief Executive Officer, Emma Walmsley. Notably, Walmsley acquired a total of 18 ordinary shares at a price of £14.5567 each, as part of the Company’s Share Reward Plan. This transaction underscores GSK’s commitment to aligning executive compensation with company performance, as these shares form part of a broader incentive structure aimed at driving shareholder value.
Additionally, Walmsley has reported the vesting of shares initially awarded in 2020 under the Company’s 2017 Performance Share Plan. This vesting follows an extended period of two years beyond the standard vesting timeline, reflecting GSK’s focus on long-term performance. Such transactions and share-related incentives illustrate GSK’s strategic efforts to motivate leadership while progressing towards achieving its operational and financial goals.
Show more
The general market has got a new strain of Trump/Kennedy induced diarrhoea |
Yes good news followed by bad news, daily. |
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) |
I'll add my two pennyworth |
Interesting points made here. I'm assuming by individuals who hold significant amounts.?..the fact it has become more noteably political is intriguing. |
#743. What has that post got to do with GSK? |
Dr Biotech |
That's ok - they'll raise it again after the shareprice reaches 1500p, 1700p etc. |
Wow, I know analysts are useless but that's a big cut. |
These brokers are good for nothing at all. |
These brokers are so clever cutting price targets after the event...10yrs old could that... |
Deutsche Bank cuts target price to 1350p from 1700p |
Further falls as Tariffs hit. |
is RFK jnr's appointment likely to be acceptable to and confirmed by congress? It seems even some Republican members are extremely sceptical of the anti-vax and FDA rhetoric, believing that vaccination is probably the biggest medical advance of all time after clean drinking water. |
I had this sell off attributed to the legal difficulties currently being experienced by AZN big wigs in China,this was then followed by the appointment of a Health Secretly in the USA who is as deluded as trump. |
First UK case was jan 2020. Part of the problem with Covid whilst obviously a serious virus, was the misinformation given by the likes of Zero Hedge and reposted by useful idiots on other forums. Doing Russia's bidding, but too thick to realise. Would have helped of course if the Chinese had been more honest and open. |
Washingmachine 16 Nov '24 - 07:08 - 33722 |
And he’s still had a far better life than 99 percent .. |
Oh and Taylor swift for the teenys |
This whole USA democrat party |
Keyno - maybe burgers are the secret to a healthy long life. |
EI - you get a tick up for that one! |
Type | Ordinary Share |
Share ISIN | GB00BN7SWP63 |
Sector | Pharmaceutical Preparations |
Bid Price | 1,433.50 |
Offer Price | 1,434.00 |
Open | 1,439.00 |
Shares Traded | 264,009 |
Last Trade | 08:58:53 |
Low - High | 1,432.00 - 1,440.50 |
Turnover | 31.38B |
Profit | 2.58B |
EPS - Basic | 0.6212 |
PE Ratio | 23.25 |
Market Cap | 59.88B |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions